September 13, 2022
Otsuka Pharmaceutical said on September 12 that its antipsychotic drug brexpiprazole has achieved the primary goal in a Japan PIII trial for the treatment of major depressive disorder. The study evaluated the efficacy and safety of the drug as an...read more